Biosimilar User Fee Negotiations Under Way; Timetable Compressed
Executive Summary
FDA has started biosimilar user fee negotiations with industry, although it does not appear the room is overcrowded with participants.
You may also be interested in...
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
FDA asks negotiators from the four industry groups to coordinate proposed changes as BsUFA renewal talks get underway.
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
Tentative agreement closely resembles FDA's original proposal.